Northwestern Mutual Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $25.6K | Sell |
81
-3
| -4% | -$707 | ﹤0.01% | 2781 |
|
|
2026
Q1 | $16.8K | Buy |
84
+46
| +121% | +$9.1K | ﹤0.01% | 2868 |
|
|
2025
Q4 | $7.18K | Hold |
38
| – | – | ﹤0.01% | 3103 |
|
|
2025
Q3 | $6.73K | Sell |
38
-25
| -40% | -$3.72K | ﹤0.01% | 3046 |
|
|
2025
Q2 | $7.16K | Sell |
63
-137
| -69% | -$14.6K | ﹤0.01% | 2900 |
|
|
2025
Q1 | $21K | Hold |
200
| – | – | ﹤0.01% | 2492 |
|
|
2024
Q4 | $21.4K | Sell |
200
-383
| -66% | -$43.3K | ﹤0.01% | 2483 |
|
|
2024
Q3 | $58.4K | Buy |
583
+17
| +3% | +$1.71K | ﹤0.01% | 2097 |
|
|
2024
Q2 | $47.7K | Sell |
566
-16
| -3% | -$1.27K | ﹤0.01% | 2102 |
|
|
2024
Q1 | $42.5K | Buy |
582
+16
| +3% | +$1.18K | ﹤0.01% | 2140 |
|
|
2023
Q4 | $40.4K | Hold |
566
| – | – | ﹤0.01% | 2129 |
|
|
2023
Q3 | $33.9K | Sell |
566
-160
| -22% | -$10.5K | ﹤0.01% | 2112 |
|
|
2023
Q2 | $52.3K | Hold |
726
| – | – | ﹤0.01% | 1963 |
|
|
2023
Q1 | $53.4K | Hold |
726
| – | – | ﹤0.01% | 1911 |
|
|
2022
Q4 | $48.5K | Sell |
726
-438
| -38% | -$28.5K | ﹤0.01% | 1926 |
|
|
2022
Q3 | $63K | Sell |
1,164
-240
| -17% | -$14.1K | ﹤0.01% | 1819 |
|
|
2022
Q2 | $78K | Sell |
1,404
-2
| -0.1% | -$113 | ﹤0.01% | 1743 |
|
|
2022
Q1 | $99K | Buy |
1,406
+2
| +0.1% | +$145 | ﹤0.01% | 1707 |
|
|
2021
Q4 | $135K | Buy |
1,404
+1,034
| +279% | +$95.5K | ﹤0.01% | 1589 |
|
|
2021
Q3 | $32K | Buy |
370
+77
| +26% | +$5.96K | ﹤0.01% | 2055 |
|
|
2021
Q2 | $24K | Hold |
293
| – | – | ﹤0.01% | 2120 |
|
|
2021
Q1 | $28K | Hold |
293
| – | – | ﹤0.01% | 1939 |
|
|
2020
Q4 | $18K | Hold |
293
| – | – | ﹤0.01% | 2004 |
|
|
2020
Q3 | $17K | Hold |
293
| – | – | ﹤0.01% | 1851 |
|
|
2020
Q2 | $20K | Sell |
293
-13
| -4% | -$824 | ﹤0.01% | 1710 |
|
|
2020
Q1 | $14K | Hold |
306
| – | – | ﹤0.01% | 1805 |
|
|
2019
Q4 | $20K | Sell |
306
-11
| -3% | -$735 | ﹤0.01% | 1733 |
|
|
2019
Q3 | $20K | Buy |
317
+11
| +4% | +$691 | ﹤0.01% | 1728 |
|
|
2019
Q2 | $22K | Buy |
306
+13
| +4% | +$957 | ﹤0.01% | 1699 |
|
|
2019
Q1 | $23K | Sell |
293
-12
| -4% | -$909 | ﹤0.01% | 1656 |
|
|
2018
Q4 | $26K | Hold |
305
| – | – | ﹤0.01% | 1505 |
|
|
2018
Q3 | $52K | Hold |
305
| – | – | ﹤0.01% | 1305 |
|
|
2018
Q2 | $39K | Buy |
+305
| New | +$34K | ﹤0.01% | 1345 |
|
|
2017
Q3 | – | Sell |
-45
| Closed | -$3K | – | 2213 |
|
|
2017
Q2 | $3K | Sell |
45
-35
| -44% | -$2.45K | ﹤0.01% | 1832 |
|
|
2017
Q1 | $5K | Buy |
80
+30
| +60% | +$1.97K | ﹤0.01% | 1717 |
|
|
2016
Q4 | $3K | Sell |
50
-107
| -68% | -$6.75K | ﹤0.01% | 1971 |
|
|
2016
Q3 | $10K | Sell |
157
-32
| -17% | -$2.35K | ﹤0.01% | 1506 |
|
|
2016
Q2 | $14K | Buy |
189
+125
| +195% | +$9.28K | ﹤0.01% | 1270 |
|
|
2016
Q1 | $4K | Buy |
+64
| New | +$3.89K | ﹤0.01% | 1718 |
|
Other funds holding LGND
JT
CAM
Northwestern Mutual Wealth Management's LGND Position: Q2 2026 in Review
Northwestern Mutual Wealth Management reduced its Ligand Pharmaceuticals (LGND) stake by 3.6% in Q2 2026, selling an estimated $707 and leaving 81 shares worth $25.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2781.
Northwestern Mutual Wealth Management first reported a position in LGND in Q1 2016 and has held it in 39 quarters since. The position peaked at $135K in Q4 2021. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Northwestern Mutual Wealth Management held 81 shares of Ligand Pharmaceuticals worth $25.6K as of Q2 2026.
- Northwestern Mutual Wealth Management sold 3 Ligand Pharmaceuticals shares in Q2 2026, an estimated $707.
- Ligand Pharmaceuticals made up ﹤0.01% of Northwestern Mutual Wealth Management's portfolio in Q2 2026, its #2781 holding.
- Northwestern Mutual Wealth Management first reported a position in Ligand Pharmaceuticals in Q1 2016 and has held it in 39 quarters since.
- Northwestern Mutual Wealth Management's Ligand Pharmaceuticals position peaked at $135K in Q4 2021.
- 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Northwestern Mutual Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.